LENZ Therapeutics, Inc. has made a significant update regarding its beneficial ownership in a recent Schedule 13D/A filing with the Securities and Exchange Commission (SEC). This update, filed on November 2, 2026, highlights changes that could impact the company’s future and investor perceptions.

LENZ Therapeutics, based in Del Mar, California, is categorized under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). The company operates on the Nasdaq under the ticker symbol LENZ. This filing is part of a series of recent submissions, including an 8-K filed on October 28, 2026, and several Schedule 13G filings earlier in the year.

The filing reveals that RA Capital Management, L.P., along with its affiliates, has amended its previous holdings in LENZ Therapeutics. Specifically, the amendment indicates that the reporting persons, which include RA Capital and key individuals like Peter Kolchinsky and Rajeev Shah, collectively hold 70,533 shares of common stock, representing approximately 0.2% of the total outstanding shares as of August 5, 2026.

"This Amendment No. 3...amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission on March 28, 2024..."

Notably, the filing states that the reporting persons ceased to be beneficial owners of more than five percent of the issuer's common stock as of October 29, 2026. This reduction in ownership is significant as it may influence how other investors view the company's stability and growth potential.

The changes reported in the filing may affect various stakeholders, including current shareholders, potential investors, and market analysts. As RA Capital Management is a notable player in the investment space, its decisions can sway market sentiment and impact trading activity in LENZ Therapeutics' stock.

Looking ahead, the filing does not specify any immediate next steps or future actions that might follow this update. However, the continuous monitoring of ownership stakes and market reactions will be crucial for understanding LENZ Therapeutics' position in the competitive biological products sector.